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ABSTRACT  
The aim of this work is the enhancement of the hydrosolubility behaviour of a poorly soluble, weakly basic drug, using itraconazole (ITZ) as a 
case example. Binary inclusion complexes of ITZ with β-cyclodextrin (β-CD) are prepared in 1:2 molar ratios of ITZ to β-CD by co-evaporation 
method. Both solubility and dissolution behaviour are compared with that of the pure drug. Ternary complexes can be obtained by adding the 
polyvinylpirrolidone (PVP) which is a highly water soluble polymer, in the ITZ/ β-CD complex formation. Actually, Solid state analysis is 
performed for all formulations and for pure ITZ applying the Fourier transforms infrared (FT-IR) spectroscopy, powder X-ray diffraction (pX-
RD) and differential scanning calorimetry (DSC). Solubility tests indicate that with all formulation, the solubility of ITZ formed with β-CD or β-
CD and PVP proved to be increased. The obtained results show that the pure drug has a poor dissolution property, and the ternary inclusion 
complexes resulted in fast and extensive release of ITZ. 
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INTRODUCTION 
Itraconazole is a triazole antifungal agent that exhibits a 
broad spectrum of activity with remarkable tolerance. 
Itraconazole is highly effective, due to its main metabolite 
namely: hydroxy-itraconazole that shows an important 
antifungal activity. It belongs to the Biopharmaceutical 
Classification System (BCS) class II and shows poor aqueous 
solubility (1 ng/ml) (1). The poor inherent drug solubility 
and slow dissolution rate in the gastrointestinal tract 
engender some difficulties in manufacturing suitable 
pharmaceutical formulations. In addition, it may also lead to 
low oral bioavailability and irreproducible clinical response 
of the drug (2). 
In the last few decades, the obtained data confirm that the 
bioavailability of BCS class II drugs can be improved by 
enhancing their solubility profiles and dissolution 
characteristics (3). Various approaches like particle size 
reduction (4), drug dispersion in carrier (5), modification of 
crystal habit (6), use of surfactants (7), self-emulsifying 
formulations (2), formation of water-soluble inclusion 
complexes (8) etc. are investigated to improve the 
dissolution profile of the poorly soluble drugs. Among them, 
the complexation with cyclodextrins (CDs) represents one of 
the advanced techniques (9). CDs are structurally 
interrelated oligosaccharides with six (α-CD), seven (β-CD) 
and eight (γ-CD) α-1,4- glucopyranose units. They have a 
lipophilic core with hydrophilic outer surface allows 
noncovalent inclusion complexes formation with 
hydrophobic drugs. This fact, is obtained by taking up all or 
some part of the moiety into the cavity [8]. These inclusion 
complexes are revealed to enhance the guest bioactive 
molecules apparent stability, solubility, dissolution rate and 
bioavailability. The β-CD is the most frequently used 
pharmaceutical cyclodextrins excipient due to its high 
availability, low cost, excellent biocompatibility, considerable 
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regulatory acceptance and preferred cavity dimension (10-
12). Note that naturally occurring cyclodextrins (α- and γ-
CD) are expensive relative to β-CD. Furthermore, recent 
report mention that β-CD derivative such HP-β-CD is more 
toxicologically benign than the natural β-CD (13),(14). 
Pioneering studies in this field show that one can increase 
complexation and solubilizing efficiencies of the β-CD (with 
less formulation bulk), by adding small quantities of a 
suitable hydrophilic polymer to a drug–β-CD system (13). 
These obtained results are due to the synergistic effect of 
polymer and β-CD on the formation of ternary complexes or 
co-complexes. The water-soluble polymers can also increase 
the apparent stability constant of the inclusion complexes 
(15). In fact, this work is an experimental demonstration of 
the credibility of novel inclusion complexes of the ITZ with β-
CD in absence and presence of polyvinylpyrrolidone (PVP-
K30) in order to improve the solubility and ITZ dissolution. I 
Actually, we investigate the formation of complexes between 
ITZ and β-CD and the effect of hydrophilic polymer (PVP-30) 
on complexation and solubilizing efficiency. In fact, Infrared 
spectroscopy (IR), differential scanning calorimetry (DSC) 
and X-ray diffraction (XRD) are carried out in order to 
characterize the ITZ and its inclusion complexes. Finally, the 
release of the drug from binary and ternary complexes at pH 
1.2 are also studied using the UV-VIS spectroscopy. 
MATERIALS AND METHODS 
MATERIALS 
ITZ and PVP-K30 are a gift sample from of SALEM 
Laboratory El- EULMA (Algeria). β-CD is purchased from 
SIGMA–ALDRICH, USA. All the other chemicals and solvents 
used are of analytical grade and procured commercially. 
Binary and Ternary Inclusion Complexes Preparation 
In a preliminary set of experiments, the optimal ITZ–β-CD 
ratio is determined in phase solubility studies. In fact, the 
obtained results from these studies indicate that the optimal 
ITZ–β-CD ratio is 1: 2. Note that the molar ratio is adopted in 
this study. Ternary complexes are made by combining PVP-
K30 at the concentration 10% of the solid complex. 
In the sequel, we explain the inclusion complexes steps. At 
the beginning, we dissolve 705 mg ITZ in a mixture of 100 
mL ethanol 96% and HCl conc (ratio 10:1) at 50 ° C (5). Then, 
in a different container, an appropriate amount of β-CD (or, 
appropriate amounts of the β-CD in the case of ternary 
complex preparation) and PVP-K30 are dissolved in distilled 
water. Furthermore, the ITZ solution is mixed with the 
excipient solution and the resulting mixture is stirred for 2 h 
until getting a clear solution. Then, the solution is evaporated 
under vacuum at temperature of 45°C and 100 rpm in a 
rotary evaporator (BUCHI, ROTAVAPOR R-215). The solid 
residue is further dried completely at 50°C for 24 hours. 
Finally, dried complex is pulverized into a fine. 
Fourier Transform Infrared (FT-IR) Spectroscopy 
The infrared spectra of the samples is obtained with an IR 
Affinity-1S, SHIMADZU spectrometer using the potassium 
bromide (KBr) disk technique (1~ 2 % w/w samples in KBr), 
They are prepared with a hydrostatic press at a force of 10 T 
cm−2 for 3 min. Note that the used interval of scanning is 
4000–400 cm−1  
Differential Scanning Calorimetry 
Differential Scanning Calorimetry (DSC) measurements for 
pure drug, β-CD and inclusion complexes are performed 
using a DSC SETARAM instrument. After being heating under 
nitrogen flow (20 ml/min) at a scanning rate of 10°C min-1 
and a temperature range of 25°C to 350°C, the samples 
between (10-15 mg) are put in sealed aluminum pans. 
However, an empty aluminium pan is consider as reference. 
X-Ray Powder Diffraction (XRPD) 
 X-ray powder diffractograms of individual components and 
the complex systems are obtained on a PAN analytical kind X’ 
PERTPRO Diffractometer. The used radiations are generated 
by a copper filter, with wavelength 1.54 A° at 40 kV and 30 
mA. From the other hand, the Glass slide are covered with 
the sample in order to be analyzed and scanned over a range 
from 1° to 60° 2θ degrees, using a scan rate of 1 degree per 
min and a steps scan of 0.02. 
Drug Content 
The drug content in the complexes obtained are determined 
by extraction using a SHIMADZU-1800 UV-visible 
spectrophotometer. A known weight of each complex (50 
mg) are placed in a 50 mL volumetric flask, and pure ethanol 
are added. The concentration of ITZ in the solution are 
determined by using the standard curve of a series of 
standard solutions of known ITZ concentrations. Extractions 
are carried out in triplicate and the drug content in the 
complex are calculated using the following formula: 
                           
                     
               
         (01) 
In Vitro Release Tests 
The in vitro release test of ITZ from all drug-carrier systems, 
and for ITZ alone was conducted using the United States 
Pharmacopeia Paddle Method (Apparatus II) on an Heidolph 
RZR 2041, an amount of each samples equivalent to 25 mg of 
ITZ is placed into a hard gelatin capsule, and then, soaked 
into 900 mL of simulated gastric medium (0.1 N HCl pH 1.2) 
for 2 h. The dissolution media maintained at 37 ± 0.5°C and 
stirred at 100 rpm. 
At suitable ranges, 5 mL of the dissolution medium are 
withdrawn, using a syringe, then, filtered through 0.45 μm 
nylon disc filter, and equivalent volumes of fresh medium are 
added to maintain the sink condition. The ITZ content is 
determined at 282 nm using an UV-VIS spectrophotometer. 
Note that, each dissolution test is performed in duplicate. 
RESULTS AND DISCUSSION 
FTIR Analysis 
For analysing the plausible interactions among ITZ, β-CD and 
PVPK30 in the solid state, the IR spectra of binary and 
ternary complexes are compared to that of pure drug (Fig. 1). 
The IR spectrum of ITZ is characterized by principal 
absorption peaks at a wavelength of 3325 cm-1 and 3111 
cm-1 match to the absorption of NH2 group. Actually, Sharp 
peak at a waverlength of 1699 cm-1 is due to vibrations of C 
= O groups. The characteristic peak in the visible waver 
length of 1442 cm-1 and 1508cm-1 related to the links C-H 
(16). 
The β-CD frequencies such 3331 cm−1, 2931 cm−1, 1153 
cm−1, and 1028 cm−1, correspond to the symmetric and 
asymmetric stretching of O-H, CH2, C-C and bending O-H 
vibration, respectively (17). The most important peaks of 
PVP-K30 are the stretching vibration of the carbonyl (CO) 
and amide (N-H) groups that characteristically appeared 
around 1678 cm−1 and 1510 cm−1, respectively (5). The 
FTIR spectra of both binary and ternary complexes exhibited 
some considerable shifting in the characteristic bands. The 
inclusion of the aromatic ring into the electron rich cavity of 
β-CD amplified the density of electron cloud, which leaded to 
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the increase in frequency. The hydrogen bonding contacts 
and Van der Waals forces in complexes may alter in the 
microenvironment, which probably decreases the frequency 
between the inclusion complex and its constituent molecules 
(18). We note that, the intensity of the skeletal bands is 
attenuated in the IR spectra of both the binary and ternary 
systems. In fact, it suggested the entire or partial entrapment 
of ITZ into the host cavity at the phase of inclusion 
complexation (8). However, the absorption band of amide 
band is much narrower for the ternary mixture case. 
Actually, we  note an important impact of  the potential 
implication of the amide group of PVP-K30 in the 
complexation process (9). Overall, the binary and ternary 
inclusion complexes do not display any new peaks meaning 
that no chemical bonds are created in the formed complexes. 
 
Fig.1. FT-IR spectra of   pure ITZ, β-CD, PVP, β-CD-ITZ 
inclusion complex (Co-evap 2) and β-CD-PVP- ITZ inclusion 
complex (Co-evap 3). 
DSC Analysis 
We note that, within the decomposition range of CD lattice,  
the physical characteristics of the guest molecules such as 
boiling, melting and sublimation point either get shifted or 
disappeared (10). The DSC thermograms of pure drug, β-CD, 
PVP-K30, binary and ternary inclusion complexes are 
illustrated in Fig.2. In the DSC curve of the pure drug, a small 
endothermic peak related to the melting point of ITZ appears 
at 166.49 °C. Thus. The DSC thermogram of β-CD shows a 
broad endotherm in the region of 120–140 °C. Therefore, this 
fact is caused by the liberation of crystal water molecules 
from the cavity (11). From the other hand, the binary and 
ternary inclusion complexes thermograms reveal an 
endothermic drug peak with less sharpness and intensity 
compared to the drug pure. This last, represents a strong 
indication of the true complex of ITZ with β-CD formation. 
Hence, PVP may partially convert to the amorphous state and 
molecularly dispersed inside the cavity of β-CD 
X-RD Studies 
P-XRD is a useful tool for the detection of β-CD complexation 
in powder or microcrystalline states. XRD studies could be 
employed to detect any change of crystallinity of a compound 
upon host–guest interactions (19). The X-ray diffraction 
patterns of drug, β-CD, PVP-K30, binary and ternary systems 
are presented in Fig. 3. P-XRD of ITZ exhibited characteristic 
peaks at 14.2°, 17.2°, 17.7°, 22.1°, 26.3°, 33.4°and 37.4° (2θ) 
that were intense and sharp, indicating its crystalline nature 
(20). The XRD pattern of β-CD revealed several sharp and 
intense diffraction peaks, which are indicative of its 
crystalline character. The complete absence of any 
diffraction peaks for PVP-K30 demonstrated its amorphous 
nature.  The obtained patterns reveal that the drug 
crystallinity of binary and ternary inclusion complexes was 
affected significantly indicating that Iitraconazole was 
present in the amorphous state in all these formulations. 
 
Fig.2. DSC curves of   pure ITZ, β-CD, PVP, β-CD-ITZ inclusion 
complex (Co-evap 2) and β-CD-PVP- ITZ inclusion complex 
(Co-evap 3). 
 
Fig.3. X-Ray diffractograms of   pure ITZ, β-CD, PVP, β-CD-ITZ 
inclusion complex (Co-evap 2) and β-CD-PVP- ITZ inclusion 
complex (Co-evap 3). 
In Vitro Drug Release Study 
In Fig4, the dissolution profiles of pure ITZ, binary and 
ternary inclusion complexes in 0.1 N HCl (with pH 1.2) are 
depicted. 
The accelerated ITZ release rate from ternary inclusion 
complexes could possibly due to the partial entrapment of 
drug molecules inside the β-CD torus. It could impart 
hydrophilic character and eventually increase the solubility 
and wettability of ITZ.  The improvement in dissolution rate 
might also be due to the conversion to the high energetic 
amorphous state and reduction in crystallinity of   ITZ 
complexation in co-evaporation method, which was verified 
from FTIR, DSC and XRD studies. In fact, the binary 
complexes exhibit lower dissolution profiles compared with 
the ternary systems. This is due to a greater inclusion and 
improvement of complexation efficiency of β-CD in the 
presence of PVP-K30. 
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Fig.4. In vitro dissolution profile of pure ITZ, β-CD-ITZ 
inclusion complex (Co-evap 2) and β-CD-PVP- ITZ inclusion 
complex (Co-evap 3). 
CONCLUSION 
A significant enhancement of the solubility and 
bioavailability of the inclusion complexes of ITZ and β-CD in 
the presence and absence of hydrophilic polymer (PVP-K30) 
are successfully obtained. The results of the study illustrate 
the formation of ITZ–β-CD inclusion complexes at a 1:2 M 
ratio in solution. The FTIR studies deny the evidence of 
chemical interactions between the drug and carriers. DSC 
and XRD studies confirmed partial morphism of the drug 
after inclusion complexation. Inclusion complexes shows 
significantly higher drug dissolution rate compared with 
pure drug. The use of β-CD in junction with PVP-K30 
improves the drug solubility and dissolution rate by 
increasing the complexation efficiency of β-CD. The final 
formulation that incorporates ternary complex of ITZ 
demonstrates acceptable physical properties and greater 
release profile compared to tablets containing pure ITZ. 
Thus, the strategy of addition of hydrophilic polymer (PVP-
k30) to ITZ–β-CD complexes may provide a promising way to 
enhance the solubility and dissolution characteristics of 
drug. Hence, the obtained result may offer promoting 
advantages of reducing the dose of the drug and the quantity 
of the needed β-CD. Moreover, hydrophilic polymer 
associated ITZ–β-CD systems constitute a new drug delivery 
system, that considerably improves the therapeutic benefits 
of ITZ for antifungal infection treatment. 
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